These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38860277)

  • 21. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
    Lee J; Kim DM; Lee A
    Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
    Liu S; Gӧnen M; Stadler ZK; Weiser MR; Hechtman JF; Vakiani E; Wang T; Vyas M; Joneja U; Al-Bayati M; Segal NH; Smith JJ; King S; Guercio S; Ntiamoah P; Markowitz AJ; Zhang L; Cercek A; Garcia-Aguilar J; Saltz LB; Diaz LA; Klimstra DS; Shia J
    Mod Pathol; 2019 Jan; 32(1):110-121. PubMed ID: 30166615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
    Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM
    Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
    Berghoff AS; Ricken G; Wilhelm D; Rajky O; Widhalm G; Dieckmann K; Birner P; Bartsch R; Preusser M
    J Neurooncol; 2016 Oct; 130(1):19-29. PubMed ID: 27436101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
    Horimoto Y; Thinzar Hlaing M; Saeki H; Kitano S; Nakai K; Sasaki R; Kurisaki-Arakawa A; Arakawa A; Otsuji N; Matsuoka S; Tokuda E; Arai M; Saito M
    Cancer Sci; 2020 Jul; 111(7):2647-2654. PubMed ID: 32449246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
    Giatromanolaki A; Banham AH; Harris AL; Koukourakis MI
    Exp Lung Res; 2019; 45(3-4):76-83. PubMed ID: 31134811
    [No Abstract]   [Full Text] [Related]  

  • 35. Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
    Pelekanou V; Barlow WE; Nahleh ZA; Wasserman B; Lo YC; von Wahlde MK; Hayes D; Hortobagyi GN; Gralow J; Tripathy D; Porter P; Szekely B; Hatzis C; Rimm DL; Pusztai L
    Mol Cancer Ther; 2018 Jun; 17(6):1324-1331. PubMed ID: 29588392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
    Škuciová V; Drahošová S; Výbohová D; Cígerová V; Adamkov M
    Pathol Res Pract; 2020 Sep; 216(9):153071. PubMed ID: 32825944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC.
    Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ
    JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) - low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer.
    Pakkanen P; Ilmarinen T; Halme E; Irjala H; Koivunen P; Pukkila M; Ventelä S; Almangush A; Birkman EM; Lindgren O; Pohjolainen V; Sjöblom N; Haglund C; Hagström J; Aaltonen LM
    Virchows Arch; 2024 Aug; 485(2):315-322. PubMed ID: 37462760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
    Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T
    Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.